AI Engines For more Details: Perplexity Kagi Labs You
Digestive Health: Haritaki is commonly used to support digestive health. It has mild laxative properties and may help alleviate constipation by promoting bowel movements. Additionally, Haritaki is believed to support overall digestive function and may help relieve symptoms of indigestion and bloating.
Antioxidant Activity: Haritaki contains a variety of antioxidant compounds, including tannins, flavonoids, and phenolic acids. These antioxidants help neutralize harmful free radicals in the body, which may reduce the risk of chronic diseases such as cancer, heart disease, and neurodegenerative disorders.
Anti-inflammatory Effects: Some research suggests that Haritaki may have anti-inflammatory properties, which could help reduce inflammation in the body. This could potentially benefit individuals with inflammatory conditions such as arthritis, inflammatory bowel disease, and asthma.
Liver Health: Haritaki is believed to have hepatoprotective effects, meaning it may help protect the liver from damage caused by toxins or disease. Studies have shown that Haritaki extract may help improve liver function and reduce liver damage in animal models.
Cardiovascular Health: Preliminary research indicates that Haritaki may have cardioprotective effects, including lowering blood pressure and cholesterol levels. These effects could potentially reduce the risk of heart disease and stroke.
Diabetes Management: Some studies suggest that Haritaki may help improve blood sugar control and insulin sensitivity, which could be beneficial for individuals with diabetes or those at risk of developing the condition.
Antimicrobial Properties: Haritaki has been shown to possess antimicrobial properties, meaning it may help inhibit the growth of harmful bacteria, viruses, and fungi. This could potentially aid in the treatment of various infections, although more research is needed in this area.
Cognitive Function: There is some evidence to suggest that Haritaki may have neuroprotective effects and could potentially help improve cognitive function and memory. These effects may be attributed to its antioxidant and anti-inflammatory properties.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Escherichia coli | Reduces |
| species | Priestia megaterium | Reduces |
| species group | Pseudomonas putida group | Reduces |
| strain | Escherichia coli G3/10 | Reduces |
| strain | Escherichia coli Nissle 1917 | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.3 | |
| Allergies | 0.8 | 0.8 | 0 |
| Allergy to milk products | 0.5 | 0.5 | 0 |
| Alopecia (Hair Loss) | 0.5 | 0.5 | |
| Alzheimer's disease | 0.5 | 0.5 | |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.5 | 0.8 | -0.6 |
| Ankylosing spondylitis | 1 | 0.3 | 2.33 |
| Anorexia Nervosa | 0.3 | 0.3 | |
| Antiphospholipid syndrome (APS) | 0.8 | 0.8 | |
| Asthma | 0.8 | 0.8 | 0 |
| Atrial fibrillation | 0.5 | 0.3 | 0.67 |
| Autism | 0.8 | 0.5 | 0.6 |
| benign prostatic hyperplasia | 0.3 | 0.3 | |
| Bipolar Disorder | 0.3 | 0.5 | -0.67 |
| Brain Trauma | 0.3 | 0.3 | 0 |
| Carcinoma | 0.3 | 0.3 | |
| Celiac Disease | 1 | 0.3 | 2.33 |
| Chronic Fatigue Syndrome | 0.8 | 0.8 | |
| Chronic Kidney Disease | 0.3 | 0.3 | |
| Chronic Lyme | 0.3 | 0.3 | |
| Chronic Urticaria (Hives) | 0.8 | 0.8 | |
| Coagulation / Micro clot triggering bacteria | 1.8 | 1.8 | |
| Colorectal Cancer | 1.5 | 1.5 | |
| Constipation | 1 | 1 | |
| COVID-19 | 1.5 | 1.5 | |
| Crohn's Disease | 1 | 0.5 | 1 |
| cystic fibrosis | 2 | 2 | |
| deep vein thrombosis | 1.8 | 1.8 | |
| Depression | 0.7 | 0.3 | 1.33 |
| Eczema | 0.5 | 0.5 | |
| Endometriosis | 1.5 | 1.5 | |
| Epilepsy | 0.3 | 0.3 | |
| Functional constipation / chronic idiopathic constipation | 1.5 | 1.5 | |
| gallstone disease (gsd) | 0.3 | 0.3 | |
| Generalized anxiety disorder | 0.8 | 0.8 | |
| Graves' disease | 0.3 | -0.3 | |
| Hidradenitis Suppurativa | 0.5 | 0.5 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1 | 1 | |
| hyperglycemia | 0.5 | 0.5 | |
| hypertension (High Blood Pressure | 0.5 | 0.3 | 0.67 |
| IgA nephropathy (IgAN) | 0.3 | 0.3 | |
| Inflammatory Bowel Disease | 1.5 | 1.5 | |
| Irritable Bowel Syndrome | 1.5 | 1.5 | |
| Liver Cirrhosis | 1.3 | 0.3 | 3.33 |
| Long COVID | 0.6 | 0.5 | 0.2 |
| Lung Cancer | 0.3 | 0.3 | |
| ME/CFS without IBS | 0.8 | 0.8 | |
| Metabolic Syndrome | 1.3 | 0.3 | 3.33 |
| Mood Disorders | 0.7 | 1 | -0.43 |
| Multiple Sclerosis | 0.5 | 0.5 | |
| myasthenia gravis | 0.3 | -0.3 | |
| Neuropathy (all types) | 0.3 | -0.3 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.5 | 0.5 | |
| Obesity | 0.8 | 0.3 | 1.67 |
| obsessive-compulsive disorder | 1.3 | 1.3 | |
| Osteoarthritis | 0.3 | 0.3 | |
| Osteoporosis | 0.3 | 0.3 | |
| Parkinson's Disease | 0.8 | 0.3 | 1.67 |
| Polycystic ovary syndrome | 0.5 | 0.5 | |
| Postural orthostatic tachycardia syndrome | 0.3 | 0.3 | |
| Psoriasis | 1 | 1 | |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.5 | 1.5 | |
| Schizophrenia | 0.3 | -0.3 | |
| Sjögren syndrome | 0.3 | 0.3 | |
| Sleep Apnea | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.5 | 1.5 | |
| Stress / posttraumatic stress disorder | 1 | 1 | |
| Systemic Lupus Erythematosus | 0.5 | 0.5 | |
| Type 1 Diabetes | 0.3 | 0.3 | 0 |
| Type 2 Diabetes | 1.3 | 0.8 | 0.63 |
| Ulcerative colitis | 1.3 | 0.5 | 1.6 |
| Unhealthy Ageing | 0.3 | 0.3 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.